【摘要】 目的：探究尤瑞克林联合阿替普酶溶栓治疗急性脑梗塞患者对神经损伤、VEGF、NO的影响。方法：选取2023年9月至2024年9月河南科技大学第二附属医院神经内科收治的100例急性脑梗塞患者，随机均分为两组，各50例。对照组(常规治疗+阿替普酶溶栓治疗)、观察组(常规治疗+阿替普酶溶栓治疗+尤瑞克林)。比较两组神经损伤情况、VEGF、NO、CRP、PCT水平。结果：治疗前，两组神经功能缺损评分比较无统计学意义(P>0.05),治疗后，两组神经功能缺损评分均显著降低(t=13.944,P<0.001、t=11.250,P<0.001),且观察组评分显著低于对照组(t=4.646,P<0.001)。治疗前，两组VEGF、NO水平比较差异不显著(P>0.05),治疗后，两组VEGF、NO水平均显著降低(t=14.201,P<0.001、t=9.811,P<0.001)、(t=20.150,P<0.001、t=13.115,P<0.001),且观察组低于对照组(t=3.591,P<0.001、t=3.210,P=0.002)。治疗前，两组CRP、PCT水平比较差异不显著(P>0.05),治疗后，两组CRP、PCT水平均显著降低(t=29.514,P<0.001、t=25.121,P<0.001)、(t=28.645,P<0.001、t=23.406,P<0.001),且观察组低于对照组(t=3.926,P<0.001、t=3.773,P<0.001)。结论：尤瑞克林联合阿替普酶溶栓治疗能够减轻急性脑梗塞患者的神经损伤，减轻机体的炎症反应，治疗情况良好。更多还原

【Abstract】 Objective: To explore the effects of Urinary kallidinogenase combined with Alteplase thrombolytic therapy on nerve injury, vascular endothelial growth factor(VEGF) and nitric oxide(NO) in patients with acute cerebral infarction. Methods: 100 patients with acute cerebral infarction admitted to the Department of Neurology, the Second Affiliated Hospital of Henan University of Science and Technology from September 2023 to September 2024 were selected for the study. They were randomly and evenly divided into two groups [control group(conventional treatment + Alteplase thrombolytic therapy) and observation group(conventional treatment + Alteplase thrombolytic therapy + Urinary kallidinogenase)], with 50 cases in each group. The nerve injury status, levels of VEGF, NO, C-reactive protein(CRP) and procalcitonin(PCT) were compared between the two groups. Results: Before treatment, there was no statistically significant difference in the neurological deficit scores between the two groups(P>0.05). After treatment, the neurological deficit scores in both groups significantly decreased(t=13.944, P<0.001; t=11.250, P<0.001), and the score in the observation group was significantly lower than that in the control group(t=4.646, P<0.001). Before treatment, there was no significant difference in the levels of VEGF and NO between the two groups(P>0.05). After treatment, the levels of VEGF and NO in both groups significantly decreased(t=14.201, P<0.001; t=9.811, P<0.001) and(t=20.150, P<0.001; t=13.115, P<0.001), and the levels in the observation group were lower than those in the control group(t=3.591, P<0.001; t=3.210, P=0.002). Before treatment, there was no significant difference in the levels of CRP and PCT between the two groups(P>0.05). After treatment, the levels of CRP and PCT in both groups significantly decreased(t=29.514, P<0.001; t=25.121, P<0.001) and(t=28.645, P<0.001; t=23.406, P<0.001), and the levels in the observation group were lower than those in the control group(t=3.926, P<0.001; t=3.773, P<0.001). Conclusion: Urinary kallidinogenase combined with Alteplase thrombolytic therapy can alleviate nerve injury and reduce the inflammatory response in patients with acute cerebral infarction, showing favorable therapeutic effects.更多还原